Clinical Observation of CABA System in the Treatment of End-stage Liver Disease With Inflammation
To Evaluate the Clinical Efficacy and Safety of the New ALSS
About this trial
This is an interventional treatment trial for To Evaluate the Clinical Efficacy and Safety of the New ALSS
Eligibility Criteria
Inclusion Criteria: ① Age 18-70; ② Patients with end-stage liver disease, including patients with acute decompensation of cirrhosis, chronic liver failure and patients with chronic and acute liver failure in Child-Pugh grade B-C; A. Acute decompensation of liver cirrhosis: ALB<35 g/L; A / G <1.0; TBIL> 120 μ mol / L; ALT> 1 × ULN and/or AST>1 × ULN; PTA <60% Ascites or hepatic encephalopathy or bleeding from esophageal varices; B. Chronic liver failure: The basis of chronic liver disease: decompensated cirrhosis; Time of onset: unlimited; Hepatic encephalopathy: with or without; Coagulation: PTA ≤ 40% or INR ≥ 1.5; Jaundice>171.1umol/L; C. Chronic plus acute liver failure: Chronic liver disease is based on: chronic hepatitis or decompensated cirrhosis; Time of onset:<4 weeks; Hepatic encephalopathy: with or without; Coagulation: PTA ≤ 40% or INR ≥ 1.5; Jaundice: TBIL ≥ 171 μ Mol/L or daily increase ≥ 17.1 μ mol/L ③ Inflammation status: the following 4 items meet any 2 items PCT≥0.50 μ g/L CRP≥40 mg/L IL-6 > 5 × ULN IL-8 > 5 × ULN ④ Understand and voluntarily sign the informed consent form approved by the Ethics Committee. Exclusion Criteria: Patients with liver malignant tumor and other tumors; People with HIV infection or other immunodeficiency diseases; Pregnant or lactating women; Patients with autoimmune disease, unstable stage of infarction caused by cardio-cerebrovascular accident, history of organ transplantation and other organ dysfunction or failure; ⑤ Patients with other serious complications (such as active bleeding, diffuse intravascular coagulation); ⑥ Those who are unable to return to the hospital for further consultation and follow-up regularly according to the research plan; Those who fail to comply with the research arrangement and sign the informed consent form; ⑧ Other conditions judged by the researcher not suitable for the group.
Sites / Locations
- Tongji HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
CABA group
control group
new artificial liver CABA system (BS330+CA280) combined with plasma exchange
BS330 combined with plasma exchange